EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube

News archive

Recent news


The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual congress (EHA25 Virtual), one of the most important haematology congresses here in Europe, was held from 11 June to 21 June 2020.

Myeloma Patients Europe (MPE) attended both ASCO2020 and EHA25 Virtual and interviewed relevant myeloma and AL amyloidosis specialists in different languages to provide an overview of the key highlights in both diseases presented during these meetings. Continue reading

 

As part of the work that Myeloma Patients Europe (MPE) is doing to provide members with support during the COVID-19 pandemic, MPE is extending the MPE Scholarship and Capacity Building Programme. Through this extension, MPE will be offering up to 10 scholarships between 2.500 and 5.000€ to develop or adapt programmes or activities related to or affected by COVID-19 or to support the organisation’s capacity, sustainability or resilience in relation to the impact of COVID-19. Continue reading

 

Data of new combinations not only in relapsed and refractory myeloma but also in upfront settings were presented in the European Hematology Association (EHA) Annual congress, held virtually from 11 June to 21 June 2020.

Myeloma Patients Europe (MPE) has interviewed Dr Maria-Victoria Mateos, Director of the Myeloma Unit at University Hospital of Salamanca-IBSAL, in Spain, to summarise the most important updates presented at this meeting for the treatment of myeloma patients. Continue reading

 

Although currently there are not approved drugs for the treatment of AL amyloidosis, important data were presented in the European Hematology Association (EHA) Annual congress, held virtually from 11 June to 21 June 2020.

Myeloma Patients Europe (MPE) has interviewed Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel), and one of the authors of the ANDROMEDA study, to summarise the most important updates presented at this meeting for the treatment of the AL amyloidosis patients. Continue reading

 

New data of the phase 3 Boston clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from 29 to 31 May 2020. This study evaluates weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in myeloma patients who have received one to three prior lines of therapy. Continue reading

 

New data of the ANDROMEDA clinical trial has been presented today in the late breaking session at the 25th European Hematology Association (EHA) Annual Congress which is happening virtual from 11 to 21 June. This study evaluates subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared to CyBorD alone in newly diagnosed patients with AL amyloidosis. Continue reading

 

The European Commission (EC) has granted marketing authorisation for daratumumab (Darzalex®) subcutaneous (SC) formulation for the treatment of adult myeloma patients. Daratumumab SC is administered as a fixed dose, which significantly reduces treatment time, from hours to approximately three to five minutes, when compared to daratumumab intravenous (IV) formulation. Continue reading

 

CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASCO 2020. Continue reading

 

The largest, and one of the most important, oncology meetings in the calendar year, the American Society of Clinical Oncology (ASCO) annual scientific meeting, was held from 29 to 31 May.

Myeloma Patients Europe attended this virtual meeting and interviewed Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, to summarise the most important myeloma highlights presented at ASCO20. Continue reading